Edition:
United States

GTX Inc (GTXI.OQ)

GTXI.OQ on NASDAQ Stock Exchange Capital Market

15.35USD
19 Jul 2018
Change (% chg)

$-0.11 (-0.71%)
Prev Close
$15.46
Open
$15.36
Day's High
$15.41
Day's Low
$15.07
Volume
16,750
Avg. Vol
38,864
52-wk High
$23.36
52-wk Low
$5.32

Select another date:

Wed, May 30 2018

Deutsche Boerse beefs up forex business with $100 million buy

BERLIN Deutsche Boerse AG is beefing up its foreign exchange business with a $100 million deal to buy GTX's Electronic Communication Network (ECN) business from GAIN Capital Holdings Inc.

Deutsche Boerse beefs up forex business with $100 mln buy

BERLIN, May 30 Deutsche Boerse AG is beefing up its foreign exchange business with a $100 million deal to buy GTX's Electronic Communication Network (ECN) business from GAIN Capital Holdings Inc.

BRIEF-GTx Updates Phase 2 Enobosarm Clinical Trial Results

* GTX UPDATES PHASE 2 ENOBOSARM CLINICAL TRIAL RESULTS IN STRESS URINARY INCONTINENCE AT 2018 AUA ANNUAL MEETING

BRIEF-GTX Inc Qtrly Loss Per Share $0.62

* GTX PROVIDES CORPORATE UPDATE AND REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

BRIEF-GTX Announces Early Completion Of Patient Enrollment In The Astrid Trial

* GTX ANNOUNCES EARLY COMPLETION OF PATIENT ENROLLMENT IN THE ASTRID TRIAL, A PHASE 2 CLINICAL TRIAL OF ENOBOSARM IN STRESS URINARY INCONTINENCE

BRIEF-GTX Inc Q4 Loss Per Share $0.43

* GTX PROVIDES CORPORATE UPDATE AND REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

BRIEF-GTx Announced New Data Demonstrating Enobosarm's Potential To Treat Stress Urinary Incontinence At SUFU 2018

* GTX ANNOUNCED NEW DATA DEMONSTRATING ENOBOSARM’S POTENTIAL TO TREAT STRESS URINARY INCONTINENCE AT SUFU 2018

BRIEF-GTx Trial Results In Stress Urinary Incontinence Accepted For Podium Presentation At SUFU

* GTX PHASE 2 ENOBOSARM CLINICAL TRIAL RESULTS IN STRESS URINARY INCONTINENCE ACCEPTED FOR PODIUM PRESENTATION AT SUFU Source text for Eikon: Further company coverage:

Select another date: